臨床外科69巻9号

2014年09月発行

特集 外科医が知っておくべき小腸疾患 手術

小腸GIST―手術を中心とした治療戦略

著者： 土屋剛史¹ 橋口陽二郎¹ 松田圭二¹ 塚本充雄¹ 福島慶久¹ 赤羽根拓弥¹ 中村圭介¹ 端山軍¹ 藤井正一¹ 野澤慶次郎¹

所属機関： ¹帝京大学医学部附属病院外科

ページ範囲：P.1098 - P.1103

【ポイント】

◆小腸GISTに対する腹腔鏡手術は，開腹手術と同等かそれ以上の成績が報告されている．

◆補助療法との組み合わせにより，生存期間の延長が期待できる．

参考文献

1）Corless CL, Fletcher JA, Heinrich MC：Biology of gastrointestinal stromal tumors. J Clin Oncol 22：3813-3825, 2004

2）日本癌治療学会，日本胃癌学会，GIST研究会（編）：GIST診療ガイドライン，第3版．金原出版，2014

3）Fong Y, Coit DG, Woodruff JM, et al：Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg 217：72-77, 1993

4）Nishimura J, Nakajima K, Omori T, et al：Surgical strategy for gastric gastrointestinal stromal tumors：laparoscopic vs. open resection. Surg Endosc 21：875-878, 2007

5）De Vogelaere K, Hoorens A, Haentjens P, et al：Laparoscopic versus open resection of gastrointestinal stromal tumors of the stomach. Surg Endosc 27：1546-1554, 2013

6）Wan P, Yan C, Li C, et al：Choices of surgical approaches for gastrointestinal stromal tumors of the stomach：laparoscopic versus open resection. Dig Surg 29：243-250, 2012

7）Karakousis GC, Singer S, Zheng J, et al：Laparoscopic versus open gastric resections for primary gastrointestinal stromal tumors （GISTs）：a size-matched comparison. Ann Surg Oncol 18：1599-1605, 2011

8）Otani Y, Furukawa T, Yoshida M, et al：Operative indications for relatively small （2-5 cm） gastrointestinal stromal tumor of the stomach based on analysis of 60 operated cases. Surgery 139：484-492, 2006

9）Ihn K, Hyung WJ, Kim HI, et al：Treatment results of small intestinal gastrointestinal stromal tumors less than 10 cm in diameter：a comparison between laparoscopy and open surgery. J Gastric Cancer 12：243-248, 2012

10）Wan P, Li C, Yan M, et al：Laparoscopy-assisted versus open surgery for gastrointestinal stromal tumors of jejunum and ileum：perioperative outcomes and long-term follow-up experience. Am Surg 78：1399-1404, 2012

11）Cai W, Wang ZT, Wu L, et al：Laparoscopically assisted resections of small bowel stromal tumors are safe and effective. J Dig Dis 12：443-447, 2011

12）Demetri GD, von Mehren M, Antonescu CR, et al：NCCN Task Force report：update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 8（Suppl 2）：S1-S41, 2010

13）The ESMO/European Sarcoma Network Working Group：Gastrointestinal stromal tumors：ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23（Suppl 7）：vii49-vii55, 2012

14）Tabrizian P, Nguyen SQ, Divino CM：Laparoscopic management and longterm outcomes of gastrointestinal stromal tumors. J Am Coll Surg 208：80-86, 2009

15）Joensuu H, Vehtari A, Riihimaki J, et al：Risk of recurrence of gastrointestinal stromal tumour after surgery：an analysis of pooled population-based cohorts. Lancet Oncol 13：265-274, 2012

16）Fletcher CD, Berman JJ, Corless C, et al：Diagnosis of gastrointestinal stromal tumors：a consensus approach. Hum Pathol 33：459-465, 2002

17）Joensuu H：Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 39：1411-1419, 2008

18）Wang D, Zhang Q, Blanke CD, et al：Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors：long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol 19：1074-1780, 2012

19）Dematteo RP, Ballman KV, Antonescu CR, et al：Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour：a randomised, doubleblind, placebocontrolled trial. Lancet 373：1097-1104, 2009

20）Joensuu H, Eriksson M, Sundby Hall K, et al：One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor：a randomized trial. JAMA 307：1265-1272, 2012

21）Heinrich MC, Corless CL, Demetri GD, et al：Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21：4342-4349, 2003

22）Debiec-Rychter M, Sciot R, Le Cesne A, et al：KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42：1093-1103, 2006

23）Heinrich MC, Owzar K, Corless CL, et al：Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor：CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 26：5360-5367, 2008

24）Gastrointestinal Stromal Tumor Meta-Analysis Group：Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors：a meta-analysis of 1640 patients. J Clin Oncol 28：1247-1253, 2010

25）Heinrich MC, Maki RG, Corless CL, et al：Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 26：5352-5359, 2008